Frequency of Helicobacter pylori infection and antibiotic resistance in patient whit acute liver decompensation

  • Milica Ristić Medicinski fakultet
  • Bojan Korica
  • Vladimir Milivojević
DOI: https://doi.org/10.5937/mp74-39601
Keywords: Helicobacter pylori, acute on chronic liver failure, acute decompensation, antibiotic resistance.

Abstract


Introduction: Helicobacter pylori (H. pylori) infection is a global healthcare challenge. In its course of infection, Helicobacter pylori infection leads to a systemic increase of post-inflammatory cytokines and can have an extragastric manifestations, affecting the worsening of metabolic and cardiovascular diseases and endangering normal liver function, especially when liver cirrhosis is present.

Aim: The aim of this study was to examine the frequency of H. pylori infection in patients with cirrhosis of the liver in stage AD or ACLF. The frequency of antibiotic resistence to clarithromycin and fluoroquinolones was also investigated.

Material and methods: We conducted prospective study with 45 patients which included both sexes. Samples of gastric mucosa were taken from all patients included in the study during the upper endoscopy and were sent to the Institute of Microbiology of the Medical Faculty in Belgrade. A molecular method, Polymerase chain reaction (PCR) was used to detect H. pylori and mutations responsible for resistance to clarithromycin and fluoroquinolones.

Results: The presence of H. pylori infection was registered in 15 decompensated patients (33,33%), while 30 (66,67%) were negative. In H. pylori positive patients, PCR detection of genotypes responsible for antibiotic resistance revealed clarithromycin resistance in 11 patients (73,33%), while fluoroquinolone resistance was detected in 7 patients (46,66%). In 6 patients (40,0%) was found a associated resistance to clarithromycin and fluoroquinolones.

 

Conclusion: H. pylori infection in cirrhotic patients with acute decompensation or ACLF has no significant effect on the severity of the clinical condition, elevated laboratory parameters and survival. Resistance rates to fluoroquinolones and clarithromycin or both antibiotics are high in decompensated patients with cirrhosis. There is a need to increase awareness of the rational use of antibiotics based on further investigations

References


  1. Aranđelović I, Banko A, Ćirković I, Čolović-Čalovski I, Gajić I, Kekić D et al. Helicobacter. In: Savić B, Mitrović S, Jovanović T, editors. Medicinska mikrobiologija. Beograd: Medicinski fakultet Univerziteta u Beogradu, CIBID, 2019. p.277-280.

  2. Diaconu S, Predescu A, Moldoveanu A, Pop CS, Fierbinteanu-Braticevici C. Helicobacter pylori infection: old and new. J Med Life. 2017;10(2):112–117.

  3. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection‐the Maastricht V/Florence consensus report. Gut. 2017;66(1):6‐30

  4. Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;70(1):40-54.

  5. Goderska K, Pena SA, Alarcon T. Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol. 2018;102(1):1-7.

  6. Pogorzelska J, Łapińska M, Kalinowska A, Łapiński TW, Flisiak R. Helicobacter pylori infection among patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2017;29(10):1161-1165.

  7. Okushin K, Tsutsumi T, Ikeuchi K, Kado A, Enooku K, Fujinaga H et al. Helicobacter pylori infection and liver diseases: Epidemiology and insights into pathogenesis. World J Gastroenterol. 2018;24(32):3617-3625.

  8. Wei L, Ding HG. Helicobacter pylori infection and peptic ulcer disease in cirrhotic patients: An updated meta-analysis. World J Clin Cases. 2021;9(24):7073-7084.

  9. Traoré O, Diarra AS, Kassogué O, Abu T, Touré S, Maïga A, Diarra M. Gastroduodenal lesions in upper gastrointestinal endoscopy associated with positive Helicobacter pylori histology in cirrhotic patients at Sikasso Hospital: prevalence study. Pan Afr Med J. 2020;37:123.

  10. Zhao B, Sheng Q-J, Qin Y, Wang X-L, Zhao H, Zhao N. Correlations of Helicobacter pylori with liver function, inflammatory factors and serum levels of FoxP3 and RORγt in patients with hepatitis B cirrhosis. Eur Rev Med Pharmacol Sci. 2021;25(1):459-465.

  11. Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398(10308):1359-1376.

  12. Crismale JF, Friedman SL. Acute Liver Injury and Decompensated Cirrhosis. Med Clin North Am. 2020;104(4):647-662.

  13. Zaccherini G, Weiss E, Moreau R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment. JHEP Rep. 2020;3(1):100176.

  14. Puentes JC, Rocha H, Nicolau S, Ferrão G. Effectiveness of the MELD/Na Score and the Child–Pugh Score for the Identification of Palliative Care Needs in Patients with Cirrhosis of the Liver. Indian J Palliat Care. 2018;24(4):526–528.

  15. N Ki, Li C, Qian Y, Sun X, Zhan Y, Zeng T et al. MELD Score Reflects the Mood, Sleep, and Daily Living Ability in Liver Transplantation Candidates: A Descriptive Study. Ann Transplant. 2020;25:926857.

  16. Philips CA, Sahney A. Oesophageal and gastric varices: historical aspects, classification and grading: everything in one place. Gastroenterol Rep (Oxf). 2016;4(3):186-195.

  17. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-388.

  18. Rabelo-Gonçalves EM, Roesler BM, Zeitune JM. Extragastric manifestations of Helicobacter pylori infection: possible role of bacterium in liver and pancreas diseases. World J Hepatol 2015;7(30):2968–2979.

  19. Kirchner GI, Beil W, Bleck JS, Manns MP, Wagner S. Prevalence of Helicobacter pylori and occurrence of gastroduodenal lesions in patients with liver cirrhosis. Int J Clin Exp Med. 2011;4(1):26-31.

  20. Feng H, Zhou X, Zhang G. Association between cirrhosis and Helicobacter pylori infection: a meta-analysis. Eur J Gastroenterol Hepatol. 2014;26(12):1309-1319.

  21. Tsai CE, Liang CM, Lee CH, Kuo YH, Wu KL, Chiu YC et al. First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. KJMS. 2016;32:397-402.

  22. Chang SS, Hu HY. Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens. World J Gastrointest Pharmacol Ther. 2015;6(4):127-136.

  23. Huang J, Cui J. Evaluation of Helicobacter pylori Infection in Patients with Chronic Hepatic Disease. Chin Med J (Engl). 2017;130(2):149-154.

  24. Kountouras J, Deretzi G, Zavos C, and Katsinelos P. Helicobacter pylori infection and liver cirrhosis: possible association with hepatic encephalopathy and/or post-hepatic encephalopathy cognitive impairment in patients with portal hypertension. Ann Gastroenterol. 2014;27(3): 285.

  25. Schulz C, Schütte K, Reisener N, Voss J, Malfertheiner P. Prevalence of Helicobacter pylori Infection in Patients with Minimal Hepatic Encephalopathy. Gastrointestin Liver Dis. 2016;25(2):191-195.

  26. Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol. 2019;25(16):1907-1912.

  27. Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front Cell Infect Microbiol. 2017;7:168.

  28. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Ann Gastroenterol. 2018;155(5):1372-1382.

  29. Liu DS, Wang YH, Zhu ZH, Zhang SH, Zhu X, Wan JH et al. Characteristics of Helicobacter pylori antibiotic resistance: data from four different populations. Antimicrob Resist Infect Control. 2019;8:192.

Published
2024/02/22
Issue
Vol. 74 No. 5 (2023): Medicinski podmladak
Section
Original Scientific Paper